跳至主要内容
临床试验/CTRI/2018/02/011905
CTRI/2018/02/011905招募中未知

A study to assess the effect of Resveratrol-Copper (R-Cu) on inflammatory cytokines in multiple myeloma patients undergoing autologous peripheral blood stem-cell transplantation.

TMC Research Administrative Council0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Male or female patients 18 years and above.
  • 2.Patients who have given written informed consent
  • 3.Patients with performance status of 0,1 or 2 (ECOG scale)
  • 4.Patients of multiple myeloma receiving melphalan- 200 mg/m2 (MEL-200 mg/m2)
  • 5.Patients who have creatinine clearance > 50 ml/min
  • 6.Patients with serum bilirubin levels < 2mg/dl and serum liver enzymes (ALT or AST or both) less than 5 times the upper limit of normal value.

排除标准

  • 1.Patients who are on NSAIDs , aspirin ,antioxidants or systemic steroids for more than 3 months and the last dose taken within the last one week.
  • 2.Patients being treated for active infection at the time of starting high dose chemotherapy

研究者

发起方
TMC Research Administrative Council

相似试验